Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram…
Cristian Massacesi Appointed Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb
Bristol Myers Squibb announced the appointment of Cristian Massacesi, M.D., as Executive…
FDA approves Bristol Myers Squibb’s Subcutaneous Opdivo Qvantig™ for various solid tumor indications
December 2024- Bristol Myers Squibb announced that the U.S. Food and Drug…
Bristol Myers Squibb Collaborates for 4th Blood Donation Drive in Dubai
Dubai, UAE- 01 October 2024- In a notable effort to highlight the…
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients
Princeton- May 2024- Bristol Myers Squibb announced ASPIRE (Accessibility, Sustainability, Patient-centric, Impact,…
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
PRINCETON- March 2024- Bristol Myers Squibb unveiled a $1.8 million initiative to…
